Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
- Ena Wang†1,
- Scott Bussom†2,
- Jinguo Chen1,
- Courtney Quinn1,
- Davide Bedognetti1, 3,
- Wing Lam2,
- Fulan Guan2,
- Zaoli Jiang2,
- Yichao Mark1,
- Yingdong Zhao4,
- David F Stroncek5,
- Jeffrey White6,
- Francesco M Marincola1Email author and
- Yung-Chi Cheng2Email author
© Wang et al; licensee BioMed Central Ltd. 2011
Received: 21 December 2010
Accepted: 11 May 2011
Published: 11 May 2011
Traditional Chinese Medicine (TCM) has been used for thousands of years to treat or prevent diseases, including cancer. Good manufacturing practices (GMP) and sophisticated product analysis (PhytomicsQC) to ensure consistency are now available allowing the assessment of its utility. Polychemical Medicines, like TCM, include chemicals with distinct tissue-dependent pharmacodynamic properties that result in tissue-specific bioactivity. Determining the mode of action of these mixtures was previously unsatisfactory; however, information rich RNA microarray technologies now allow for thorough mechanistic studies of the effects complex mixtures. PHY906 is a long used four herb TCM formula employed as an adjuvant to relieve the side effects associated with chemotherapy. Animal studies documented a decrease in global toxicity and an increase in therapeutic effectiveness of chemotherapy when combined with PHY906.
Using a systems biology approach, we studied tumor tissue to identify reasons for the enhancement of the antitumor effect of CPT-11 (CPT-11) by PHY906 in a well-characterized pre-clinical model; the administration of PHY906 and CPT-11 to female BDF-1 mice bearing subcutaneous Colon 38 tumors.
We observed that 1) individually PHY906 and CPT-11 induce distinct alterations in tumor, liver and spleen; 2) PHY906 alone predominantly induces repression of transcription and immune-suppression in tumors; 3) these effects are reverted in the presence of CPT-11, with prevalent induction of pro-apoptotic and pro-inflammatory pathways that may favor tumor rejection.
PHY906 together with CPT-11 triggers unique changes not activated by each one alone suggesting that the combination creates a unique tissue-specific response.
Although traditional Chinese medicine (TCM) has been applied for thousands of years in Asia, its recognition by Western countries rests upon objective documentation of its value. To date, no systematic evaluation of TCM has provided conclusive proof of efficacy, though several studies suggest beneficial applications in certain patient populations . In cancer patients, TCM has been applied predominantly to control cancer-associated symptoms or decrease treatment-related toxicity. However, it was observed that some herbal products display anticancer properties . Most TCM products currently used in cancer therapy display a broad range of biological effects including pro-apoptotic activity, inhibition of angiogenesis and boosting of immune response. For instance, it was recently observed that a significant proportion of ginseng's biological activity in vivo is exerted through modulation of innate immunity .
PHY906 is a TCM formulation that has been used for the last 1,800 years to treat distressing conditions of the gastrointestinal tract. Several preclinical animal models tested the ability of PHY906 to increase the therapeutic window of chemotherapy by decreasing its gastrointestinal side effects. Recently, we documented strong protective effects by PHY906 on chemotherapy-induced intestinal toxicity [4, 5]. Moreover, pre-clinical and early-phase clinical trials of PHY906 in combination with chemotherapy in patients with advanced hepatocellular carcinoma , pancreatic cancer and other gastrointestinal malignancies  have yielded promising results.
To date, no experimentally-validated hypothesis about the adjuvant anti-tumor mechanisms of PHY906 given during chemotherapy has been proposed. Extensive biochemical characterization and standardization of PHY906, which includes a mixture of four herbs: Glycyrrhiza uralensis Fisch (G), Paeonia lactiflora Pall (P), Scutelleria baicalensis Georgi (S), and Ziziphus jujuba Mill (Z) under GMP conditions, using Phytomics technology indicates that the product can be prepared with a high degree of consistency  greatly improving the interpretability of pre-clinical and clinical results. Chemical and biological characterization of PHY906 demonstrated that a large number of bioactive substances are present in the four herbal preparations. Because of the pharmacokinetic differences in the processing and creation of structurally different chemicals, and the pharmacodynamic differences of new metabolites vs. parent compounds, the biological effects identified in vitro are difficult to ascribe as a relevant anti-cancer mechanism in vivo . Moreover, none of the herbs display alone in vivo the effectiveness displayed by their combination. This complexity has hampered the design of mechanistic studies evaluating specific biological pathways in the context of the cumulative effects of PHY906, particularly when its effects are evaluated in vivo where different active components have the opportunity to interact with cancer and normal host's cells simultaneously. Therefore, a first effort toward the understanding of the mechanisms of action of PHY906 should frame the overall effects of the herb in vivo using global transcriptional profiling. Thus, we scanned alterations of the transcriptional program induced by PHY906 following its administration as a single agent and in combination with Irinotecan (CPT-11) in a well-characterized pre-clinical model in which both agents were administered to female BDF-1 mice bearing subcutaneous Colon 38 tumor implants. Its effects were compared with those observable in normal tissues such as autologous liver and spleen. The study demonstrated that PHY906 or CPT-11 alone induces significant transcriptional changes in the tumor and in normal tissues that are exquisitely tissue-specific. PHY906 significantly amplifies the effects of CPT-11 in the tumor tissue. Most importantly, PHY906 together with CPT-11 triggers unique changes not triggered by each one alone and this may explain the enhanced anti-tumor activity of the combination.
Materials and methods
Murine Colon 38 cells were transplanted subcutaneously into four- to six-week-old female BDF1 mice (Charles River Laboratories, Wilmington, MA) as previously described . After 10 to 14 days, mice with tumor sizes of 150-300 mm3 were selected. PHY906 was given orally over 72 hours (500 mg/kg) while CPT-11 (360 mg/kg) was administered intra-peritoneally on Day 0. In the combination group, the first dose of PHY906 was given 30 minutes prior to CPT-11 administration. Mice (BDF1 bearing Colon 38 tumors) were terminated by cervical dislocation 72 hours after initiation of drug treatment. Tumor tissue was removed and divided and either frozen for total RNA isolation or placed in 10% neutral buffered formalin for histological analysis. All animal experiments were carried out in accordance with an approved Yale University Institutional Animal Care and Use Committee (IACUC) protocol. Murine Colon 38 cell lines were provided by Dr. Giuseppe Pizzorno, Ph.D., Pharm.D (Translational Science, Nevada Cancer Institute, USA).
Gene expression microarray analysis
Total RNA was extracted from mouse tissues using TRIzol® (Invitrogen) and 3 μg were amplified by in vitro transcription . Pooled total RNA from mixed normal mouse tissues was used as universal reference. Both test and reference RNA were labeled respectively with Cy5 and Cy3 using ULS aRNA Fluorescent Labeling kit (Kreatech, Netherlands) and co-hybridized to a 36K mouse oligonucleotide arrays (Operon, Version 4.0 Mouse Genome Oligo Set containing 35,852 probes representing approximately 25,000 genes). Hybridization was carried out overnight at 42°C and the microarray slides were scanned by GenePix Pro 4.0 (Axon, Sunnyvale, CA).
Microarray data analysis and statistics
The resulting data files were analyzed using BRBArray Tools . Raw data were background subtracted. The complete experimental data set including 111 samples from mouse tumor, liver and spleen was filtered retaining transcripts with at least 80% spot presence with spot size requirement >20 μM, and intensity in at least one channel > 200 and override the other channel to 200 to avoid high ratio artifact. Intensity ratios above 64 were truncated. Data were normalized using median normalization across the array. This filter selected 18,549 transcripts that were used as the master data set for subsequent analyses. A high stringency comparison (significance p-value cutoff < 0.001) was used to identify transcripts with a high likelihood of differential expression among experimental groups and a low stringency gene enrichment (cutoff p-value < 0.05) was used for pathway analysis. For all experiments, multivariate (global) permutation test (pt = 10,000 pts) was applied to test whether the number of transcripts obtained in each analysis was above the likelihood expected by chance. Gene functions were congregated into pathways and networks using Ingenuity Pathways Analysis (IPA) software (v7.6). Canonical pathways enriched in differentially expressed transcripts were ranked according their significance (-log p value).
For each sample, 0.5 to 1 ug of total RNA was converted into cDNA using M-MLV reverse transcriptase according to manufactures instructions using random primers. All individual primer sets for genes of interest were designed using NCBI primer design on exons junction when possible. Primer pairs were then run through Beacon Designer™ Free qPCR Designer Program http://www.premierbiosoft.com/jsp/marketing/FreeToolLogin.jsp?PID=1 to eliminate primer-dimers that may interfere with assay. Primers were then checked using melt curve analysis for one product and their efficiency determined using iCycler software. Real Time PCR was performed on BioRad-i-Cycler system using Sybr® green as dye and Phusion® DNA Polymerase with the following condition: 98°C 1 min followed by (98°C :10 sec, 60°C :10 sec 72°C :10 sec) X either 38 or 44 cycles. Sample serial dilutions served as source for relative standard curve. Samples (n = 10/group) were run in duplicate. For each sample, the relative copy number for the gene of interest is divided by the relative copy number for B-actin. Final result is presented as relative expression of the gene relative copy number compared to the mean of the same gene in PBS control group. Results calculated using Excel and graphed in GraphPad Prism. Primer sequences are shown in Additional file 1, Table S1
Tissues were embedded in OCT, stored in liquid nitrogen and cut into 10 μm sections at -18°C. The tissue sections were fixed in acetone at 4°C for 10 minutes and stored at -80°C. Upon immunohistochemistry staining, sections were post-fixed in methanol with 3% acetic acid for 20 minutes. After two 5 minute washes in PBS, the sections were bathed for 20 minutes in 3% H2O2 in Tris Buffered Saline with 0.05% Tween-20 followed by incubation for 1 hour in blocking buffer (Gelatin 0.1%, BSA 1%, Goat serum 10% in TBS). Primary antibody F4/80 (abcam #ab16911 rat monoclonal-BM8) was diluted 1:10 in blocking buffer and incubated with the tissue sections overnight at 4°C. After washing 4 times in PBS and TBS at room temperature, rat on mouse HRP-Polymer Kit (#RT517G, BIOCARE) was incubated with the section for 20 minutes. After washing, the HRP polymer that conjugates to the probe was added for 20 minutes followed by DAB development. Sections were then counter stained with hematoxylin.
Effect of PHY906 on tumor growth and weight in CPT-11 treated BDF-1 mice bearing colon 38 tumors
Comparison between the tumor, spleen and liver
Transcriptional patterns observed in the 4 treatment cohorts were compared among liver, spleen and tumor samples. In the absence of treatment (PBS cohort), the transcriptional program of the tumors was remarkably different from normal liver and spleen. Multiple dimensional scaling (MDS) based on the complete data set, clearly separated tissues (Figure 1b). Gene enrichment based on an unpaired t test at a low cutoff stringency (p-value < 0.05) identified 7,856 transcripts differentially expressed by tumors compared to the two normal tissues combined. Of these genes, 7,348 had an annotated function and, therefore, could be used for Ingenuity Pathway Analysis (IPA). A large number of canonical pathways (104 over a total of 318) were significantly altered (Fisher's exact test threshold p2-value < 0.05) in the tumor microenvironment compared to the normal tissues. Most affected cellular growth and proliferation, intra-cellular signaling and cellular stress. Ranking of pathways according to percentage of genes affected identified several immune-related canonical pathways (IL-22, JAK/STAT, IFN, IL-3 and VEGF signaling) within the top 15 confirming that chronic inflammation is associated with the neoplastic process. While pathways predominantly associated with the oncogenic process were enriched with over-expressed transcripts (cleavage of mRNA, polyamine regulation in colon cancer, DNA methylation and protein ubiquitination), canonical pathways associated with immune function were more balanced in their frequency of up- or down-regulated genes.
Because of the disparities among the transcriptional profiles of various tissues, it became obvious that direct cross comparisons of the effects of treatment among different tissues would not be informative; rather indirect comparisons could be made by defining the effects of various treatments in each tissue and subsequently comparing different tissues. A four way Anova (F test, cutoff p-value < 0.001) and univariate t tests (cutoff p-value < 0.001 and < 0.05) were performed among (between) treatments for the three tissues to obtain a general estimate of the number of transcripts proportionally affected in each condition (Additional file 2, Table S2). Both CPT-11 and PHY906 affected a larger number of genes in the spleen than in the tumor or liver. In all tissues, differences were observed among treatment groups and PHY906 treatment alone bore significant and independent effects that were statistically significant by permutation (pt) test. Moreover, PHY906 significantly altered the effects of CPT-11 in all tissues. There was little overlap among the effects of the 4 treatments on the tumor or other tissues. The patterns that were dominant in the tumor microenvironment (innate immune response and activation of nuclear factor kappa B; NF-kB) were minimally affected in the other two organs. Thus, as expected, the effects of either PHY906 and/or CPT-11 are highly tissue specific.
Analysis of therapy on the tumor tissues
Summary of differentially expressed tumor genes among treatment groups.
Number of genes < 0.001 and
for <0.001 cutoff†
PBS vs PHY906
PBS vs CPT-11
PBS vs CPT-11+PHY906
CPT-11 vs CPT-11+PHY906
Effect of PHY906 on tumors
Effect of CPT-11 on tumors
Effect on tumors of PHY906 when combined to CPT-11
High stringency class comparison between CPT-11+PHY906 and PBS treated animals (t test cutoff p-value < 0.001) identified 798 differentially expressed transcripts. Enrichment analysis (threshold p-value of < 0.05) identified 3,347 genes (3,190 with an annotated function) (Table 1). Both data sets suggested that the combination reversed the down-regulation of the expression of genes related to innate immune responses observed with CPT-11 treatment. Comparison of the 15 most affected canonical pathways suggested that the primary differences between combination therapy and CPT-11 alone were quantitative, with more genes being up regulated by the combined treatment (Additional file 3, Figure. S3c). Side by side comparison of immune pathways (Figure 2d) clearly demonstrated that the combination enhanced the expression of pro-inflammatory functions. Thus, PHY906 enhanced the pro-inflammatory effects of the chemotherapy acting in an opposite direction than when given alone (Figure 2b). Overlay of the PHY906 plus CPT-11 effects (Figure 4d) on the CPT-11 modulated NF-kB network clearly demonstrated an up regulation of genes associated with NF-kB immune function including the activation of the MyD-88/IRF-5 signaling network. Moreover, a diminished suppression of IRF-1 was observed with an average ratio going from 0.3 with CPT-11 vs PBS to 0.64 when CPT-11+PHY906 were compared to PBS.
PHY906-specific effects during CPT-11 therapy on tumors
To better understand the specific contribution of PHY906 when used in combination with CPT-11, we compared tumor samples from animals treated with CPT-11 to those treated with CPT-11+PHY906 and identified 93 genes that were differentially expressed (pt test p-value < 0.001). Enrichment analysis identified 1,556 genes differentially expressed (pt test p-value < 0.001, 1,477 annotated) (Table 1). IPA analysis demonstrated that the overlap in the ranking of most affected canonical pathways was limited to pro-inflammatory pathways such as IFN, IL-9 and JAK/STAT signaling, suggesting that the addition of PHY906 to CPT-11 treatment predominantly affected pathways associated with the immune switch from chronic to acute inflammation (Additional file 3, Figure. S3d). These effects could be best appreciated by the side by side comparison (Figure 2e) where PHY906 proportionally enhanced all immune regulatory pathways associated with acute inflammatory processes. The best example was the complete reversal of the expression of genes associated with IFN signaling with up-regulation of the IFN-α receptor, JAK1, STAT-2, IRF-1 and IRF-5.
Combining the analysis of CPT-11+PHY906 vs CPT-11 and CPT-11+PHY906 vs PBS one observes that there is a striking immunologic effect of PHY906 when given in combination with CPT-11 that is an activation of the IRF-5/Myd88 pathways and the reversal of the suppression of the STAT-1/IRF-1 pathways (Figure 4e). This preliminary data suggests that PHY906 works in the context of chemotherapy by enhancing inflammation through IRF-5 while blocking the anti-apoptotic effects likely activated by cancer cells through the suppression of IRF-1 expression .
Validation of immune cell infiltration in tumor by immunohistochemistry
Validation by real-time qPCR of selected transcripts of relevance to this study
It has been suggested that conventional chemotherapy induces cancer cell elimination not only through direct cytostatic or cytotoxic mechanisms but also through modulation of host's immune cell function . DNA damage caused by therapies that disrupt cell cycle has direct immune stimulatory effects. Tumors do not regress in immune depleted animals treated with doxorubicin given in combination with IL-12 and several other cytotoxic agents can induce powerful immune responses against cancer . Although the effects of chemotherapeutic agents is currently believed to be due to the induction of cellular damage and subsequent activation of innate immune responses, no information is available about the transcriptional signatures within the tumor microenvironment that could support this hypothesis. A few experimental models suggest that chemotherapy acts by inducing the release of cytokines and chemokines such as CXCL-9/Monokine induced by IFN-γ (MIG), CXCL-10/IFN-γ -induced protein 10 kDa (IP-10), CCL-2/MCP-1, CCL-3/MIP-1α, CCL-5/RANTES, IL-6, IFN-γ and TNF [21, 22]. This study assessed the effect of chemotherapy at the global transcript level.
The study focused on the early effects of treatment which are more likely to provide mechanistic information about the up-stream events leading to the observed phenomenology as we have previously shown in preclinical  or clinical models [24, 25]. The results support the current view that chemotherapy acts, at least in part, by modulating immune responses (Figure 2c) resulting in enhancement of immune infiltrates (Figure 5c). Of note, CPT-11, modulated the high mobility group box-1 pathway, confirming the central role that it plays in the induction of anti-cancer activity by chemotherapeutics through activation of innate immunity [26, 27]. The effects of CPT-11 on immune responses at the dose used in this study were, however, ambivalent with a balanced proportion of genes related to inflammatory processes being up-regulated or down-regulated over their baseline activation within the tumor microenvironment (Figure 2). CPT-11 effects were centered on the regulation of apoptosis by NF-kB including activation of genes related to mitochondrial fatty acid oxidation, sodium pump regulation such as the ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), the tumor necrosis factor receptor super-family member 12A (Fn14/TNFRF12A/TWEAKR) inducer of apoptosis, the tumor necrosis factor AIP3 interacting protein 2 (TNIP2), the inositol 1,4,5-trisphosphate 3-kinase B (ITPKB). These genes have predominantly pro-apoptotic effects, while genes with clear anti-apoptotic effects and related to cell growth such as lactate dehydrogenase A (LDHA) and the transferrin receptor (TFRC) were down-regulated; thus, it appears that CPT-11 counteracts the anti-apoptotic activity of NF-kB inducing apoptosis and alterations of cellular metabolism. In contrast, pro-inflammatory pathways downstream of NF-kB regulation were predominantly down-regulated at this early time point perhaps because the tissue damage induced by chemotherapy had not reached a sufficient intensity to induce immune activation (Figure 4a and 5c). The complex activation of NF-kB-dependent transcripts leading to apoptosis and/or inflammation deserves discussion. The anti-apoptotic effects of NF-kB are balanced in cancer by the tumor suppressor effects of IRF-1 and/or IRF-5 which directly inhibit its cyto-protective activity [14, 28, 29]. In particular, IRF-5 can sensitize tumors treated with CPT-11 to DNA damage-induced apoptosis and cell death . In baseline conditions IRF-5 was found to be down-regulated in Colon 38 tumors compared to normal tissues while the expression of IRF-1 was neutral compared with other tissues (Figure 2a). We speculate that CPT-11 activates pro-apoptotic pathways by suppressing IRF-1 expression (Figure 5c) while leaving unaltered the constitutive down-regulation of IRF-5 in these tumors. The combined down-regulation of the two tumor suppressor genes may allow NF-kB to partially counteract apoptosis while the acute inflammatory process fostering cancer rejection is hampered by the down-regulation of the IRFs .
PHY906 was originally used to treat gastrointestinal symptoms including those related to the toxic effects of chemotherapy. Work from our group  demonstrates that PHY906 can revert intestinal damage caused by CPT-11 through the anti-inflammatory properties of the herb and the repopulation of intestinal progenitor cells. This study, did not address the complex effects that PHY906 has on the gut that will be addressed in the future, but focused on the early transcriptional changes observable at the tumor site. To address whether the effects of PHY906 were tissue specific, we compared the transcriptional changes at the tumor site with those in two normal organs characterized by high metabolic activity (liver) or immunologic functions (spleen). These organs were also exposed to systemic concentrations of orally administered PHY906 and/or CPT-11 (i.p.) different from those experienced by the front line exposure in the gut. Comparisons of the transcriptional profiles of the three tissues demonstrated clear baseline differences independent of any treatment which made cross comparisons of the various treatment effects among various tissues uninformative. Nevertheless, this approach clearly demonstrated that the effect of PHY906 and of chemotherapy with CPT-11 is exquisitely tissue-specific with very little overlap of pathways regulated by the various combinations in different tissues. This is not surprising since each tissue is enriched with different potential target cells that may react differently to CPT-11 or PHY906.
While tissues were not micro-dissected or single cell preparations were not obtained ex vivo, a general overview of the global changes induced by PHY906 could be obtained. In particular, we were interested in understanding how a herbal product with supposed anti-inflammatory properties could paradoxically increase the anti-tumor effects induced by chemotherapy; this concept is opposed to the current hypothesis of how the host immune system cooperates with the effects of chemotherapy . Besides its immune modulatory effects on inflammation, PHY906 could have a direct impact on cancer cell survival by modulating apoptosis, autophagy or necrosis in cells undergoing exposure to chemotherapy. Although we have previously observed that PHY906 could inhibit tumor cell growth in culture (Additional file 4, Data in S4), the in vitro data could be misleading since not all the chemicals in PHY906 are necessarily absorbed into circulation and some that are absorbed will be metabolized in vivo. However, it is possible that some of the in vitro effects mediated by PHY906 on cancer cells may be retained. In vivo, PHY906 induced a predominantly downward modulation of transcription and down-regulation of the pro-inflammatory activity naturally present within the tumor. This anti-inflammatory effect was corroborated by the decreased amount of tissue macrophages seen by immunohistochemistry (Figure 5b).This is in line with its postulated functions in the gut . Since no tumor regression was seen in response to PHY906 administered alone, it is unlikely that these effects have relevant bearing on tumor regression.
The surprising finding of this study emerged when we examined the effects of the combination of PHY906 plus CPT-11. Contrary to the anti-inflammatory properties observed when administered alone, PHY906 strongly counteracted the CPT-11 induced depression of inflammation through the IRF-mediated pathways. In particular, PHY906 counteracted the down-regulation of the master regulator of the pro-inflammatory switch and apoptosis IRF-1 [14, 31, 32]. Additionally, PHY906 enhanced the expression of IRF-5, another potent pro-inflammatory transcription factor associated with immune-mediated, tissue-specific rejection [33–36] as well as induction of apoptosis of CPT-11 treated cancers . Thus, we speculate that PHY906, in line with other experimental models , enhances the anti-tumor properties of chemotherapy with CPT-11 by imparting a pro-inflammatory state that is not observed in the same CPT-11 naïve cancerous tissue. The reasons for the contradictory behavior remain to be ascertained, although it is likely that they involve a modulation of the balance between the anti-apoptotic and pro-inflammatory functions of NF-kB while, at the same time, inducing the expression of interferon stimulated genes with chemo-attractant properties such as CCL-2/MCP-1 and CCL-5/RANTES .
In summary, this is the first study of the effects of a traditional Chinese compound PHY906 on tumors undergoing chemotherapy with CPT-11. The results demonstrated that 1) PHY906 and CPT-11 alone induce significant alterations in all tissues evaluated (tumor, liver and spleen); 2) PHY906 and CPT-11 alone generally induce repression of transcription in the tumors; 3) the effects of PHY906 are reverted in the presence of a chemotherapeutic agent such as CPT-11, with a high prevalence of transcripts being up-regulated; 4) PHY906 bears a general immune-suppressive effect in tumors when given alone but, when given in combination, it results in a relative pro-inflammatory pro-apoptotic effect; 5) the pro-inflammatory, pro-apoptotic effects of PHY906 when given in combination are exquisitely tumor-specific as they are not observed in the gut as we recently described  nor in other normal tissues such as liver or spleen as observed in this study. It should be emphasized that this striking dichotomy in the behavior of this herbal product suggest its usefulness to enhance the therapeutic window for chemotherapeutics as it can decrease toxicity in normal tissues while at the same time promoting cell death within the tumor microenvironment.
This study was in part supported by Grant UO-63477 from the National Cancer Institute (NCI) and National Institutes of Health (NIH), USA; Dr. Yung-Chi Cheng is a Fellow of the National Foundation for Cancer Research.
- Manheimer E, Wieland S, Kimbrough E, Cheng K, Berman BM: Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies. J Altern Complement Med. 2009, 15: 1001-1014. 10.1089/acm.2008.0414.PubMed CentralView ArticlePubMed
- Efferth T, Li PC, Konkimalla VS, Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007, 13: 353-361. 10.1016/j.molmed.2007.07.001.View ArticlePubMed
- Lee DC, Yang CL, Chik SC, Li JC, Rong JH, Chan GC, Lau AS: Bioactivity-guided identification and cell signaling technology to delineate the immunomodulatory effects of Panax ginseng on human promonocytic U937 cells. J Transl Med. 2009, 7: 34-10.1186/1479-5876-7-34.PubMed CentralView ArticlePubMed
- Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu S-H, Cheng Y-C: The four-herb chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Science Transl Med. 2010, 2: 45ra59.View Article
- Callaway E: How an 1,800-year-old herbal mix heals the gut. Nature News. 2011, [http://www.nature.com/news/2010/100818/full/news.2010.417.html]
- Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Jiang Z, Su T, Cheng YC: Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009, 29: 4083-4092.PubMed
- Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC: Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010, 17: 161-169. 10.1016/j.phymed.2009.12.016.View ArticlePubMed
- Tilton R, Paiva A, Guan J, Marathe R, Jiang Z, van Eindhoven W, Prusoff Z, Bjoraker J, Wang H, Liu SH, Cheng YC.: A comprehensive platform for quality control of botanical drugs (Phytomics QC) - A case study of Huanggi Tang (HGT) and PHY906. Chinese Medicine. 2010, 5: 30-10.1186/1749-8546-5-30.PubMed CentralView ArticlePubMed
- Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E, Cheng YC: Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass Spectrometry (LC/MS/MS). J Chromatogr A. 2010, 1217: 5785-5793. 10.1016/j.chroma.2010.07.045.PubMed CentralView ArticlePubMed
- Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nature Biotech. 2000, 17: 457-459.
- Simon R, Lam A, LI MC, Ngan M, Menenzes S, Zhao Y: Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform. 2007, 3: 11-17.PubMed CentralPubMed
- Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu S-H, Jiang Z, Cheng YC, Chu E, et al: A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorec Cancer. 2010.
- Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, Kochanek PM, Greenberger JS, Pitt B, Shvedova AA, Borisenko G: Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med. 2009, 46: 1439-1453. 10.1016/j.freeradbiomed.2009.03.004.PubMed CentralView ArticlePubMed
- Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H, Lee MS: Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J Biol Chem. 2001, 276: 13153-13159. 10.1074/jbc.M007646200.View ArticlePubMed
- Lee JH, Chun T, Park SY, Rho SB: Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta. 2008, 1783: 1654-1662. 10.1016/j.bbamcr.2008.04.006.View ArticlePubMed
- Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T: Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 2005, 434: 243-249. 10.1038/nature03308.View ArticlePubMed
- Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 2003, 63: 6424-6431.PubMed
- Barnes BJ, Kellum MJ, Field AE, Pitha PM: Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol. 2002, 22: 5721-5740. 10.1128/MCB.22.16.5721-5740.2002.PubMed CentralView ArticlePubMed
- Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro' V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 5: 55-10.1186/1471-2164-5-55.PubMed CentralView ArticlePubMed
- Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008, 8: 59-73. 10.1038/nri2216.View ArticlePubMed
- Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005, 65: 11752-11761. 10.1158/0008-5472.CAN-05-1658.View ArticlePubMed
- Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van ED, Fitzgerald KA, Young HA, Ching LM, Vogel SN: The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med. 2007, 204: 1559-1569. 10.1084/jem.20061845.PubMed CentralView ArticlePubMed
- Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, Monsurró V, Buller RM, Stroncek DF, Wang E, Szalay AA, Marincola FM: Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. BMC Genomics. 2009, 10: 301-10.1186/1471-2164-10-301.PubMed CentralView ArticlePubMed
- Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002, 3: RESEARCH0035.PubMed CentralView ArticlePubMed
- Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A, Fetsch PA, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, Marincola FM: Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 2006, 8: R8.View Article
- Dong XE, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007, 30: 596-606. 10.1097/CJI.0b013e31804efc76.View Article
- Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L: The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007, 220: 47-59. 10.1111/j.1600-065X.2007.00573.x.View ArticlePubMed
- Suk K, Kim YH, Chang I, Kim JY, Choi YH, Lee KY, Lee MS: IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett. 2001, 495: 66-70. 10.1016/S0014-5793(01)02335-3.View ArticlePubMed
- Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008, 26: 535-584. 10.1146/annurev.immunol.26.021607.090400.View ArticlePubMed
- Hu G, Mancl ME, Barnes BJ: Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res. 2005, 65: 7403-7412. 10.1158/0008-5472.CAN-05-0583.View ArticlePubMed
- Wang E, Worschech A, Marincola FM: The immunologic constant of rejection. Trends Immunol. 2008, 29: 256-262. 10.1016/j.it.2008.03.002.View ArticlePubMed
- Honda K, Taniguchi T: IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006, 6: 644-658. 10.1038/nri1900.View ArticlePubMed
- Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT: The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005, 280: 17005-17012. 10.1074/jbc.M412584200.View ArticlePubMed
- Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, Behr MA, Fitzgerald KA, Sassetti CM, Kelliher MA: NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog. 2009, 5: e1000500-10.1371/journal.ppat.1000500.PubMed CentralView ArticlePubMed
- Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K: Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem Biophys Res Commun. 2007, 354: 1045-1051. 10.1016/j.bbrc.2007.01.090.View ArticlePubMed
- Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA: IRF5 is required for late-phase TNF secretion by human dendritic cells. Blood. 2010
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/4/38/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.